← Back to headlines
Amgen shares fall after Novartis heart drug trial setback and downgrade
Amgen's stock dropped after Novartis reported a trial failure for its Lp(a) heart therapy, raising concerns about Amgen's similar drug, leading to a downgrade by BMO.
8 Sept, 10:52 — 8 Sept, 14:26
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (37/100)3 sources25/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left1
Left (1)
Yahoo
Center
Right2
Right (2)
seeking-alphaBarron's
Far R
Geographic diversity— 1 region4/34
US3
ℹAll sources from US region
Sources
Showing 3 of 3 sources
Barron'sHigh8h ago
Novartis Stock: 3 September Drug Trial Setbacks and More Pain on the Way - Barron's
Novartis Stock: 3 September Drug Trial Setbacks and More Pain on the Way Barron's
Read full article →YahooMostly Factual11h ago
Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade
Read full article →seeking-alphaMixed7h ago
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
Read full article →Coverage Timeline
First report: Yahoo · 8 Sept, 10:52|Full coverage: 3 · 4h|Window: 4h
Left-leaningCenterRight-leaning
Related Stories
Declassified Documents Reveal NYC Downplayed Post-9/11 Air Toxicity at Ground Zero
30m ago
Spanish FA Launches Fertility Support for Female Players and Referees
2h ago
Pamela Anderson Reveals Hepatitis C Diagnosis Was a 'Death Sentence'
2h ago
Roivant shares soar after inhaled lung disease drug succeeds in mid-stage trial
5h ago